Antibodies targeting immune checkpoint inhibitors may be effective in improving survival outcome in patients with small cell lung cancer (SCLC), a new study suggests (Clin Lung Cancer 2016 Jul 9. [Epub ahead of print]).
The investigators hoped to answer the question of whether patients with SCLC benefit from immune checkpoint inhibitors, as is the case in patients with non-small cell lung cancer (NSCLC).
They assessed data from early-phase SCLC trials that demonstrated clinical activity and